Novel Anticoagulants in Dialysis Patients for Atrial Fibrillation

“

The availability of novel anticoagulants, particularly apixaban, have been a major advance in the prevention of stroke in atrial fibrillation. There is a pressing need for a high-quality randomized trial of apixaban 2.5 mg po bid versus warfarin adjusted dose versus matching double dummy placebo to fully assess the risks and benefits in this population.

”